세계의 결절성 양진 치료 시장 분석과 예측 : 치료 유형별, 투여 경로별, 진단 방법별, 결절성 발진 유형별, 유통 채널별, 지역별(-2032년)

According to Stratistics MRC, the Global Prurigo Nodularis Treatment Market is accounted for $2.2 billion in 2025 and is expected to reach $3.4 billion by 2032 growing at a CAGR of 6.3% during the forecast period. Prurigo Nodularis treatment focuses on alleviating intense itching, reducing nodular lesions, and improving quality of life. Management typically involves topical therapies such as corticosteroids and anti-itch creams, systemic medications like immunomodulators or biologics (e.g., dupilumab), and phototherapy. Dermatologists tailor treatment plans based on severity and underlying conditions. Patient education on avoiding scratching and maintaining proper skin care is essential. Regular follow-ups help monitor progress and adjust therapies, aiming for long-term symptom control and skin healing.

Market Dynamics:

Driver:

Rising prevalence and increased diagnosis rates of prurigo nodularis

The increasing incidence of prurigo nodularis, particularly among individuals with chronic dermatological and systemic conditions, is a major growth driver. Enhanced awareness among healthcare providers and patients has led to earlier and more accurate diagnoses. This trend is further supported by improved access to dermatology consultations and diagnostic tools. As the disease burden grows, so does the demand for effective therapies, especially those targeting the underlying immunological mechanisms rather than just symptomatic relief.

Restraint:

High cost of advanced therapies and limited access in emerging markets

Despite promising developments in biologics and targeted treatments, the high cost of these therapies remains a significant barrier. In developing regions, limited reimbursement frameworks and uneven healthcare infrastructure restrict patient access. Additionally, gaps in physician training and awareness about newer treatment modalities further hinder adoption. These challenges collectively slow market penetration and limit the reach of innovative solutions.

Opportunity:

Increasing investment in R&D for targeted biological and small molecule therapies

Pharmaceutical companies are intensifying their focus on developing biologics and small molecule drugs that disrupt the itch-scratch cycle and modulate immune responses. Regulatory support, such as breakthrough therapy designations, is accelerating clinical trials and approvals. Strategic collaborations between industry and academia are also expanding the therapeutic pipeline. These efforts are expected to yield safer, more effective treatments and broaden the market's scope.

Threat:

Limited reimbursement policies for novel therapies

While biologics like dupilumab and nemolizumab show strong efficacy, their adoption is constrained by restrictive reimbursement policies, especially outside North America and Western Europe. Payers remain cautious due to high costs and limited long-term data. This financial uncertainty discourages widespread use and may slow innovation. Without broader insurance coverage, many patients may continue relying on less effective conventional treatments.

Covid-19 Impact:

The pandemic had a dual impact on the prurigo nodularis treatment market. On one hand, supply chain disruptions and reduced dermatology visits temporarily slowed treatment uptake. On the other, heightened awareness of chronic conditions and the expansion of teledermatology encouraged remote consultations and continuity of care. The crisis also accelerated digital health adoption, enabling better disease monitoring and patient engagement, which ultimately supported market recovery and growth

The systemic treatments segment is expected to be the largest during the forecast period

The systemic treatments segment is expected to account for the largest market share during the forecast period due to their superior efficacy in managing severe and refractory cases. These treatments offer long-term relief by targeting inflammatory pathways, making them preferable over topical agents. The growing availability of approved biologics and ongoing clinical trials for novel agents are reinforcing this markets leadership boosting its presence.

The chronic nodular prurigo segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the chronic nodular prurigo segment is predicted to witness the highest growth rate. Chronic nodular prurigo, characterized by persistent, treatment-resistant itch and nodules, demands advanced therapeutic approaches. The debilitating nature of the condition drives patients to seek long-term solutions, boosting demand for biologics and immune modulators. Increased diagnosis and awareness are further fueling the growth of the market.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share attributed to rising dermatological disease prevalence, expanding healthcare infrastructure, and growing access to biologic therapies. Countries like China, India, and Japan are investing in dermatology modernization and clinical research, enhancing treatment availability. Government initiatives promoting skin health and early diagnosis are also contributing to regional dominance.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR driven by its advanced healthcare infrastructure and early adoption of biologic therapies. The United States leads in clinical research, with a high volume of ongoing trials for novel agents such as IL-31 and IL-4/13 inhibitors, which are reshaping the therapeutic landscape. Canada, while slightly more conservative in reimbursement policies, is expanding access through public health initiatives and regulatory approvals for biologics like Dupixent. The region's emphasis on chronic disease management and digital dermatology platforms is accelerating market growth.

Key players in the market

Some of the key players in Prurigo Nodularis Treatment Market include AbbVie Inc, Amgen Inc, AstraZeneca, Bayer AG, Dermavant Sciences, Eli Lilly and Company, Galderma, GlaxoSmithKline plc, Incyte Corporation, Johnson & Johnson Services, Inc, Leo Pharma, Merck & Co., Inc, Novartis AG, Pfizer Inc, Regeneron Pharmaceuticals, Inc, Sanofi, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, and UCB S.A.

Key Developments:

In June 2025, AbbVie revealed its intention to acquire Capstan Therapeutics to bolster its immunology portfolio, marking another strategic move into next-generation therapies. The deal reflects AbbVie's ongoing commitment to expanding its presence in autoimmune and inflammatory diseases.

In May 2025, Regeneron agreed to acquire genetic testing company 23andMe following its bankruptcy filing, securing its personal genome service and health-research assets. The deal set to close in Q3 2025 retains all staff and establishes an independent privacy ombudsman to oversee consumer data protections

In April 2025, Regeneron announced a long-term partnership worth over $3 billion with Fujifilm Diosynth Biotechnologies to nearly double its biologics production capacity at Holly Springs, NC, and expand manufacturing footprint nationwide.

Treatment Types Covered:

• Topical Treatments
• Systemic Treatments
• Cryotherapy
• Phototherapy
• Pulsed Dye Laser
• Intralesional Corticosteroid Injections
• Medical Tape/Occlusion
• Other Treatment Types

Route of Administrations Covered:

• Topical
• Oral
• Parenteral

Diagnosis Methods Covered:

• Skin Biopsy
• Blood Tests
• Dermoscopy
• Other Diagnosis Methods

Type of Nodular Prurigos Covered:

• Chronic Nodular Prurigo
• Acute Nodular Prurigo
• Subacute Nodular Prurigo

Distribution Channels Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Prurigo Nodularis Treatment Market, By Treatment Type

• 5.1 Introduction
• 5.2 Topical Treatments
  • 5.2.1 Corticosteroids
  • 5.2.2 Calcineurin Inhibitors
  • 5.2.3 Capsaicin Cream
  • 5.2.4 Emollients/Moisturizers
  • 5.2.5 Non-prescription Itch Relief
• 5.3 Systemic Treatments
  • 5.3.1 Antihistamines
  • 5.3.2 Immunosuppressants
  • 5.3.3 Anticonvulsants/Neuropathic Pain Medications
  • 5.3.4 Antidepressants
  • 5.3.5 Biologics
    • 5.3.5.1 IL-4Ra inhibitors
    • 5.3.5.2 IL-31RA antagonists
    • 5.3.5.3 JAK Inhibitors
    • 5.3.5.4 Other Biologics
  • 5.3.6 Opioid Receptor Antagonists
  • 5.3.7 Neurokinin 1 (NK1) Receptor Antagonists
  • 5.3.8 Oral Corticosteroids
• 5.4 Cryotherapy
• 5.5 Phototherapy
• 5.6 Pulsed Dye Laser
• 5.7 Intralesional Corticosteroid Injections
• 5.8 Medical Tape/Occlusion
• 5.9 Other Treatment Types

6 Global Prurigo Nodularis Treatment Market, By Route of Administration

• 6.1 Introduction
• 6.2 Topical
• 6.3 Oral
• 6.4 Parenteral

7 Global Prurigo Nodularis Treatment Market, By Diagnosis Method

• 7.1 Introduction
• 7.2 Skin Biopsy
• 7.3 Blood Tests
• 7.4 Dermoscopy
• 7.5 Other Diagnosis Methods

8 Global Prurigo Nodularis Treatment Market, By Type of Nodular Prurigo

• 8.1 Introduction
• 8.2 Chronic Nodular Prurigo
• 8.3 Acute Nodular Prurigo
• 8.4 Subacute Nodular Prurigo

9 Global Prurigo Nodularis Treatment Market, By Distribution Channel

• 9.1 Introduction
• 9.2 Hospital Pharmacies
• 9.3 Retail Pharmacies
• 9.4 Online Pharmacies

10 Global Prurigo Nodularis Treatment Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 AbbVie Inc
• 12.2 Amgen Inc.
• 12.3 AstraZeneca
• 12.4 Bayer AG
• 12.5 Dermavant Sciences
• 12.6 Eli Lilly and Company
• 12.7 Galderma
• 12.8 GlaxoSmithKline plc
• 12.9 Incyte Corporation
• 12.10 Johnson & Johnson Services, Inc.
• 12.11 Leo Pharma
• 12.12 Merck & Co., Inc.
• 12.13 Novartis AG
• 12.14 Pfizer Inc.
• 12.15 Regeneron Pharmaceuticals, Inc.
• 12.16 Sanofi
• 12.17 Takeda Pharmaceutical Company Limited
• 12.18 Teva Pharmaceutical Industries Ltd.
• 12.19 UCB S.A.